Temporal Trends and Outcomes of Transcatheter Mitral Valve Repair and Surgical Mitral Valve Intervention.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
12 2020
Historique:
received: 03 03 2020
revised: 15 05 2020
accepted: 18 05 2020
pubmed: 6 7 2020
medline: 13 8 2021
entrez: 5 7 2020
Statut: ppublish

Résumé

There is a paucity of data regarding the contemporary changes in the uptake and outcomes of transcatheter mitral valve repair (TMVR) and surgical mitral valve repair/replacement (SMVR). We queried the NIS database (2012-2016) to identify hospitalizations for TMVR and SMVR. We reported the temporal trends for uptake of TMVR and SMVR and their in-hospital outcomes. The analysis included 77,645 hospitalizations: 8760 (11.3%) for TMVR and 68,885 (88.7%) for SMVR. Those undergoing TMVR were older and had a higher prevalence of comorbidities, but shorter length of stay (5.5 ± 8.8 vs. 14.3 ± 13.8, p < 0.001) compared with SMVR. There was a marked increase in the number of TMVRs over time (from 420 in 2012 to 3850 in 2016; +917%; P Real world data showed a steady increase in the number of TMVR and SMVR procedures. Overall, TMVR was associated with low in-hospital mortality and complications rates. Despite older age and increased comorbidities, TMVR patients had lower in-hospital mortality and shorter length than their SMVR counterparts.

Sections du résumé

BACKGROUND
There is a paucity of data regarding the contemporary changes in the uptake and outcomes of transcatheter mitral valve repair (TMVR) and surgical mitral valve repair/replacement (SMVR).
METHODS
We queried the NIS database (2012-2016) to identify hospitalizations for TMVR and SMVR. We reported the temporal trends for uptake of TMVR and SMVR and their in-hospital outcomes.
RESULTS
The analysis included 77,645 hospitalizations: 8760 (11.3%) for TMVR and 68,885 (88.7%) for SMVR. Those undergoing TMVR were older and had a higher prevalence of comorbidities, but shorter length of stay (5.5 ± 8.8 vs. 14.3 ± 13.8, p < 0.001) compared with SMVR. There was a marked increase in the number of TMVRs over time (from 420 in 2012 to 3850 in 2016; +917%; P
CONCLUSION
Real world data showed a steady increase in the number of TMVR and SMVR procedures. Overall, TMVR was associated with low in-hospital mortality and complications rates. Despite older age and increased comorbidities, TMVR patients had lower in-hospital mortality and shorter length than their SMVR counterparts.

Identifiants

pubmed: 32620401
pii: S1553-8389(20)30293-1
doi: 10.1016/j.carrev.2020.05.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1560-1566

Informations de copyright

Published by Elsevier Inc.

Auteurs

Ayman Elbadawi (A)

Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, United States of America.

Islam Y Elgendy (IY)

Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.

Ahmed H Mohamed (AH)

Department of Internal Medicine, Rochester General Hospital, Rochester, NY, United States of America.

Mohamed F Almahmoud (MF)

Division of Cardiovascular Medicine, University of South Carolina, Charleston, SC, United States of America.

Mohmed Omer (M)

Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, United States of America.

A Abuzaid (A)

Division of Cardiovascular Medicine, University of California San Francisco, San Francisco, CA, United States of America.

Karim Mahmoud (K)

Department of Internal Medicine, Houston Medical Center, Warner Robins, GA, United States of America.

Gbolahan O Ogunbayo (GO)

Department of Cardiovascular Medicine, University of Kentucky, Lexington, KY, United States of America.

Ali Denktas (A)

Division of Cardiovascular Medicine, Baylor School of Medicine, Houston, TX, United States of America.

David Paniagua (D)

Division of Cardiovascular Medicine, Baylor School of Medicine, Houston, TX, United States of America.

Subhash Banerjee (S)

Division of Cardiovascular Medicine, University of Texas South Western, Dallas, TX, United States of America.

Hani Jneid (H)

Division of Cardiovascular Medicine, Baylor School of Medicine, Houston, TX, United States of America. Electronic address: Jneid@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH